These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26283275)

  • 1. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.
    Arnetz L; Hage C; Ekberg NR; Alvarsson M; Brismar K; Norhammar A; Mellbin L
    Growth Horm IGF Res; 2015 Dec; 25(6):298-303. PubMed ID: 26283275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
    Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
    J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.
    Arnetz L; Hage C; Brismar K; Catrina SB; Norhammar A; Lundman P; Wallander M; Ryden L; Mellbin L
    Diab Vasc Dis Res; 2016 Jul; 13(4):307-11. PubMed ID: 27190088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy.
    Kuo CS; Chen HS
    Diabetes Res Clin Pract; 2024 Sep; 215():111814. PubMed ID: 39127303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K; Gaillard T; Schuster D
    Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.
    Kaku K; Kadowaki T; Terauchi Y; Okamoto T; Sato A; Okuyama K; Arjona Ferreira JC; Goldstein BJ
    Diabetes Obes Metab; 2015 Nov; 17(11):1033-41. PubMed ID: 26094974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in non-glycemic responses to improved insulin sensitivity by pioglitazone treatment in patients with type 2 diabetes.
    Arnetz L; Dorkhan M; Alvarsson M; Brismar K; Ekberg NR
    Acta Diabetol; 2014 Apr; 51(2):185-92. PubMed ID: 23389468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
    Ferjan S; Janez A; Jensterle M
    Endocr Pract; 2018 Jan; 24(1):69-77. PubMed ID: 29144805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.
    Grant SJ; Chang DH; Liu J; Wong V; Kiat H; Bensoussan A
    BMC Complement Altern Med; 2013 May; 13():104. PubMed ID: 23672597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
    Osei E; Zandbergen A; Brouwers PJAM; Mulder LJMM; Koudstaal P; Lingsma H; Dippel DWJ; den Hertog H
    BMJ Open; 2021 Sep; 11(9):e046113. PubMed ID: 34531203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
    Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.
    Moreira-Lucas TS; Duncan AM; Rabasa-Lhoret R; Vieth R; Gibbs AL; Badawi A; Wolever TM
    Diabetes Obes Metab; 2017 Jan; 19(1):133-141. PubMed ID: 27717236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials.
    Tajima N; Eiki JI; Okamoto T; Okuyama K; Kawashima M; Engel SS
    J Diabetes Investig; 2020 May; 11(3):640-646. PubMed ID: 31743602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes.
    Hage C; Lundman P; Rydén L; Mellbin L
    Eur J Prev Cardiol; 2013 Aug; 20(4):549-54. PubMed ID: 22456695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.